Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients

NCT00044525 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Breast Cancer, Metastatic

Interventions

DRUG: BAY59-8862 (Cytotoxic Taxane)

Sponsor

Bayer